Specialized Program Of Research Excellence (SPORE) in Leukemia

$68,242P50FY2017CANIH

Washington University, Saint Louis MO

Investigators

Linked publications & trials

Paper 39367170 Paper 38968137 Paper 38960949 Paper 38848040 Paper 38832931 Paper 38805302 Paper 38737793 Paper 38713894 Paper 38659818 Paper 38618679 Paper 38405731 Paper 38215755 Paper 37967363 Paper 37838759 Paper 37798328 Paper 37686186 Paper 37556118 Paper 37477653 Paper 37425790 Paper 37399471 Paper 37339484 Paper 37079859 Paper 36967480 Paper 36922625 Paper 36797416 Paper 36711871 Paper 36477272 Paper 36416736 Paper 35697686 Paper 35366991 Paper 35041928 Paper 34873300 Paper 34845035 Paper 34797911 Paper 34730109 Paper 34670359 Paper 34546980 Paper 34469727 Paper 34423790 Paper 34304247 Paper 34244297 Paper 34215620 Paper 34187852 Paper 34134472 Paper 34077722 Paper 33986022 Paper 33832946 Paper 33704937 Paper 33689684 Paper 33490978 Paper 33434062 Paper 33415078 Paper 33256911 Paper 33241677 Paper 32929488 Paper 32859220 Paper 32826231 Paper 32739655 Paper 32736382 Paper 32614951 Paper 32537114 Paper 32510326 Paper 32492428 Paper 32468720 Paper 32398790 Paper 32347921 Paper 32324888 Paper 32197069 Paper 32152466 Paper 32102931 Paper 32092137 Paper 31935283 Paper 31563575 Paper 31402259 Paper 31204302 Paper 31109944 Paper 31080550 Paper 30927979 Paper 30792212 Paper 30553776 Paper 30515263 Paper 30467844 Paper 30466751 Paper 30452487 Paper 30431463 Paper 30380364 Paper 30207916 Paper 30204297 Paper 30054334 Paper 30026477 Paper 29959414 Paper 29752065 Paper 29724719 Paper 29691471 Paper 29567774 Paper 29515031 Paper 29483708 Paper 29386642 Paper 29367708 Paper 29365324

Abstract

DESCRIPTION (provided by applicant): The Washington University SPORE in Leukemia is a highly dynamic translational cancer research program that focuses specifically on leukemias and myelodysplastic syndromes (MDS). We have assembled an outstanding group of investigators with complementary expertise in basic and clinical leukemia research. In this SPORE, we leverage expertise in cancer genomics, immunology, and hematopoiesis to develop innovative translational research in leukemia. Our long term goal is to develop novel biomarkers and treatments for leukemias and MDS and to recruit and promote innovative translational leukemia research. To achieve these goals, the following specific aims are proposed. Aim 1. To exploit recent advances in cancer genomics to develop novel biomarkers and treatments for leukemias and MDS. Washington University has been at the forefront of genomic studies in AML and MDS. Through sequencing of primary acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) genomes, we identified several novel recurring mutations of genes involved in DNA methylation (DNMT3A and IDH1) and RNA splicing (U2AF1). This basic research has led to the development of the following two translational SPORE projects. Project 1. Molecular determinants of decitabine responsiveness Project 3. Development of RNA splicing modulators for myelodysplastic syndromes and AML. Aim 2. To leverage local expertise in immunology and hematopoiesis to develop novel treatments for leukemias and myelodvsplastic syndromes. Institutional expertise in basic immunology and hematopoiesis research has led to the development of two innovative translational projects in leukemia. Project 2. Targeting the bone marrow microenvironment in acute lymphocytic leukemia. Project 4. Epigenetic modulation of graft versus host disease and graft versus leukemia. Aim 3. To enhance the infrastructure that supports translational leukemia research. This SPORE will support the following Shared Research Resources: 1) Core A. Biospecimen Processing; 2) Core B. Biostatistics; and 3) Core C. Administration. Aim 4. To recruit and train new investigators in translational research. Aim 5. To facilitate inter-SPORE collaboration.

View original record on NIH RePORTER →